Entities associated with One Equity Partners (OEP) increased their position in AdaptHealth Corp. through two block purchases that together amount to $4.4 million in market value. The transactions occurred over two consecutive days in March 2026 and were executed at prices within a narrow band of $9.81 to $9.95 per share.
On March 19, 2026, the OEP-affiliated entities acquired 727 shares at a weighted average price of $9.9417, representing a total consideration of $7,227. The following day, March 20, 2026, they purchased a substantially larger parcel of 447,100 shares at a weighted average price of $9.9121, for a total of $4,431,700. Combined, the two transactions equal approximately $4.44 million.
After recording these purchases, the reporting owners now hold 16,312,698 shares of AdaptHealth. At the time of reporting, AdaptHealth shares were trading at $11.29, up nearly 9% over the previous week and trading close to a 52-week high of $11.75.
Public filings list the reporting owners as a group of One Equity Partners entities along with an individual named Richard M. Cashin Jr. The roster of reporting owners includes OEP VII GP, L.L.C.; OEP AHCO Investment Holdings, LLC; ONE EQUITY PARTNERS VII, L.P.; ONE EQUITY PARTNERS VII-A, L.P.; ONE EQUITY PARTNERS VII-B, L.P.; OEP VII Project A Co-Investment Partners, L.P.; OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P.; OEP VII General Partner, L.P.; and CASHIN RICHARD M JR.
These purchases arrive in the wake of AdaptHealth's reported fourth-quarter 2025 results, which presented a mixed picture. The company posted an adjusted loss per share of -$0.76, missing the consensus estimate of $0.36 and producing an earnings surprise of -311.11%. Revenue for the quarter, however, was reported at $846.3 million, exceeding the expected $832.5 million by 1.66%.
Analysts have reacted with measured views. RBC Capital retained an Outperform rating on AdaptHealth and set a $13.00 price target, noting the stock's decline following the earnings release and the guidance for 2026. Leerink Partners similarly kept an Outperform rating but lowered its price target to $12.00, citing mixed fourth-quarter 2025 results. Both firms referenced the company’s continuing operating and standardization initiatives when discussing their views.
In addition to the transaction details and recent earnings, a market analysis platform flags AdaptHealth as appearing undervalued relative to its Fair Value and highlights upside potential. That platform provides detailed valuation metrics and a set of ProTips for investors seeking additional context on AHCO.
Key takeaways
- OEP-related entities executed two purchases of AHCO stock on March 19 and March 20, 2026, totaling $4.4 million at prices between $9.81 and $9.95 per share.
- Following the trades, reporting owners hold 16,312,698 shares; the stock trades near recent highs at $11.29 and close to a 52-week high of $11.75.
- AdaptHealth's Q4 2025 results were mixed with a sizable EPS miss but modest revenue outperformance; analysts maintain Outperform ratings with differing price targets.
Risks and uncertainties
- Significant EPS shortfall in Q4 2025 introduces near-term earnings uncertainty for AdaptHealth and may affect investor sentiment in healthcare equipment and services sectors.
- Analyst divergence on price targets and the company’s ongoing operating and standardization initiatives create uncertainty about near-term valuation and execution.